Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Alessandro Coppola

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5550-1756; OpenAlex author ID A5057394271. Sources: OpenAlex.

Their work

Papers
28 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 6 papers · 2024: 10 papers · 2025: 2 papers · 2026: 2 papers

Papers 28

  1. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  4. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  5. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  6. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  7. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  8. The impact of intensified staging and combined therapies in locally advanced pancreatic cancer: a secondary analysis of prospective studies. Co-author DOI 10.1097/js9.0000000000000755↗
  9. Endoscopic workup in pancreatic cancer. First author DOI 10.1097/js9.0000000000000777↗
  10. Preoperative low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical outcomes in pancreatic cancer patients undergoing surgery: … Co-author DOI 10.1097/js9.0000000000000989↗
  11. Treatment of oligo-metastatic pancreatic ductal adenocarcinoma to the liver: is there a role for surgery? A narrative review. Co-author DOI 10.1097/js9.0000000000001665↗
  12. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  13. Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era? Co-author DOI 10.21037/hbsn-24-603↗
  14. Novel Biomarkers in Pancreatic Cancer. Co-author DOI 10.3390/cancers16030628↗
  15. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection. Co-author DOI 10.1097/js9.0000000000000558↗
  16. An invited commentary on 'Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adeno… Co-author DOI 10.1097/js9.0000000000000607↗
  17. Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review. First author DOI 10.21037/jgo-22-1034↗
  18. Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072013↗
  19. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going. Co-author DOI 10.3390/jcm12113677↗
  20. Role of preoperative sarcopenia in predicting postoperative complications and survival after pancreatoduodenectomy for pancreatic cancer. Co-author PMID 36810297↗
  21. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives. Co-author DOI 10.3390/biomedicines10092091↗
  22. Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins. First author DOI 10.3390/cancers14194658↗
  23. Role of Neoplastic Markers in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm11216509↗
  24. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Co-author DOI 10.3389/fonc.2021.690580↗
  25. Detection of Pancreatic Ductal Adenocarcinoma by Ex Vivo Magnetic Levitation of Plasma Protein-Coated Nanoparticles. Co-author DOI 10.3390/cancers13205155↗
  26. A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers12082016↗
  27. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. First author DOI 10.1007/s00464-016-5222-1↗
  28. Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma. First author DOI 10.1007/s00268-016-3412-6↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Damiano D. Caputo · 12 shared papers, 2020–2024 · strength 2.14
  2. Roberto Coppola · 10 shared papers, 2020–2024 · strength 1.54
  3. Vincenzo La Vaccara · 9 shared papers, 2021–2024 · strength 1.53
  4. Roberto Cammarata · 5 shared papers, 2022–2023 · strength 0.88
  5. Daniela Pozzi · 4 shared papers, 2021–2024 · strength 0.82
  6. Sara Ramella · 5 shared papers, 2020–2024 · strength 0.75
  7. Michele Fiore · 5 shared papers, 2020–2024 · strength 0.75
  8. Roberto Valente · 2 shared papers, 2024 · strength 0.55
  9. Erica Quagliarini · 3 shared papers, 2021–2023 · strength 0.46
  10. Giulio Caracciolo · 3 shared papers, 2021–2023 · strength 0.46
  11. Urban Arnelo · 1 shared paper, 2024 · strength 0.31
  12. Paolo Sapienza · 1 shared paper, 2023 · strength 0.31
  13. Luca Digiacomo · 2 shared papers, 2021–2022 · strength 0.27
  14. Sofia Svensson Di Giorgio · 1 shared paper, 2024 · strength 0.24
  15. Jun Yoshino · 1 shared paper, 2024 · strength 0.24
  16. Asif Halimi · 1 shared paper, 2024 · strength 0.24
  17. Francesco Ardito · 1 shared paper, 2024 · strength 0.24
  18. Felice Giuliante · 1 shared paper, 2024 · strength 0.24
  19. Pauline Celine Raoul · 1 shared paper, 2024 · strength 0.23
  20. Maria Cristina Mele · 1 shared paper, 2024 · strength 0.23
  21. Emanuele Rinninella · 1 shared paper, 2024 · strength 0.23
  22. Marco Cintoni · 1 shared paper, 2024 · strength 0.23
  23. Giampaolo Tortora · 1 shared paper, 2024 · strength 0.23
  24. Francesco Giovinazzo · 1 shared paper, 2023 · strength 0.18
  25. Rolando Maria D’Angelillo · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.